Sort   by:  
 Page size 
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of im...
ORGANISM(S): Homo Sapiens 
2022-02-28 | PXD029167 | panorama
Sort   by:  
 Page size